Santen SAS
Clinical trials sponsored by Santen SAS, explained in plain language.
Now part of
Santen Pharmaceutical Co., Ltd.
4536
TOKYO
A subsidiary of Santen Pharmaceutical, focusing on ophthalmology products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Tiny tube could tame glaucoma without daily drops Results expected Sep 2027 (estimated)